Federica Compostella

Prof. Federica Compostella

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2017 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
Federica CompostellaFederica Compostella
Federica Compostella
OPOlimpia Pitirollo
Olimpia Pitirollo
ASAlessandro Silvestri
Alessandro Silvestri
LPLaura Polito
Laura Polito
Glyco-gold nanoparticles combine in a single entity the peculiar properties of gold nanoparticles with the biological activity of carbohydrates. The result is an exciting nanosystem, able to mimic the natural multivalent presentation of saccharide moieties and to exploit the peculiar optical properties of the metallic core. In this review, we present recent advances on glyco-gold nanoparticle applications in different biological fields, highlighting the key parameters which inspire the glyco nanoparticle design.

26 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MFMariarosaria Ferraro
Mariarosaria Ferraro
IDIlda D’annessa
Ilda D’annessa
EMElisabetta Moroni
Elisabetta Moroni
GMGiulia Morra
Giulia Morra
Antonella PaladinoAntonella Paladino
Antonella Paladino
GCGiorgio Colombo
Giorgio Colombo

23 November 2016 in Nanomedicine
Verified
Journal Article
Closed access
MVMaria Vetro
Maria Vetro
DSDodi Safari
Dodi Safari
SFSilvia Fallarini
Silvia Fallarini
KSKorrie Salsabila
Korrie Salsabila
MLMartina Lahmann
Martina Lahmann
Federica CompostellaFederica Compostella
Federica Compostella
Aim: Nanotechnology-based fully synthetic carbohydrate vaccines are promising alternatives to classic polysaccharide/protein conjugate vaccines. We have prepared gold glyco-nanoparticles (GNP) bearing two synthetic carbohydrate antigens related to serotypes 19F and 14 of Streptococcus pneumoniae and evaluated their immunogenicity in vivo. Results: A tetrasaccharide fragment of serotype 14 (Tetra-14), a trisaccharide fragment of serotype 19F (Tri-19F), a T-helper peptide and d -glucose were loaded onto GNP in different ratios. Mice immunization showed that the concomitant presence of Tri-19F and Tetra-14 on the same nanoparticle critically enhanced the titers of specific IgG antibodies toward type 14 polysaccharide compared with GNP exclusively displaying Tetra-14, while no IgG antibodies against type 19F polysaccharide were elicited. Conclusion: This work is a step forward toward synthetic nanosystems combining carbohydrate antigens and immunogenic peptides as potential carbohydrate-based vaccines. Graphical abstract

24 May 2007 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
JSJens Schümann
Jens Schümann
FFFederica Facciotti
Federica Facciotti
Luigi PanzaLuigi Panza
Luigi Panza
MMMario Michieletti
Mario Michieletti
Federica CompostellaFederica Compostella
Federica Compostella
GLGennaro De Libero
Gennaro De Libero
Deficiencies in enzymes of the lysosomal glycosphingolipid degradation pathway or in lysosomal lipid transfer proteins cause an imbalance in lipid metabolism and induce accumulation of certain lipids. A possible impact of such an imbalance on the presentation of lipid antigens to lipid‐reactive T cells has only been hypothesized but not extensively studied so far. Here we demonstrate that presentation of lipid antigens to, and development of, lipid‐reactive CD1d‐restricted NKT cells, are impaired in mice deficient in the lysosomal enzyme β‐galactosidase (βGal) or the lysosomal lipid transfer protein Niemann‐Pick C (NPC) 2. Importantly, the residual populations of NKT cells selected in βGal–/– and NPC2–/– mice showed differential TCR and CD4 repertoire characteristics, suggesting that differential selecting CD1d:lipid antigen complexes are formed. Furthermore, we provide direct evidence that accumulation of lipids impairs lipid antigen presentation in both cases. However, the mechanisms by which imbalanced lipid metabolism affected lipid antigen presentation were different. Based on these results, the impact of lipid accumulation should be generally considered in the interpretation of immunological deficiencies found in mice suffering from lipid metabolic disorders.

1 January 2015 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
ECElena Chiricozzi
Elena Chiricozzi
MCMaria Grazia Ciampa
Maria Grazia Ciampa
GBGiuseppina Brasile
Giuseppina Brasile
Federica CompostellaFederica Compostella
Federica Compostella
APAlessandro Prinetti
Alessandro Prinetti
LMLaura Mauri
Laura Mauri
Lactosylceramide (LacCer) has been shown to contain very long fatty acids that specifically modulate neutrophil properties. The interactions between LacCer and proteins and their role in cell signalling processes were assessed by synthesizing two molecular species of azide-photoactivable, tritium labelled LacCer having acyl chains of different lengths. The lengths of the two acyl chains corresponded to those of a short/medium- and very long fatty acid, comparable to the lengths of stearic and lignoceric acids, respectively. These derivatives, designated C18-[3H]LacCer-(N3) and C24-[3H]LacCer-(N3), were incorporated into the lipid rafts of plasma-membranes of neutrophilic differentiated HL-60 (D-HL60) cells. C24-[3H]LacCer-(N3), but not C18-[3H]LacCer-(N3), induced the phosphorylation of Lyn and promoted phagocytosis. Incorporation of C24-[3H]LacCer-(N3) into plasma membranes, followed by illumination, resulted in the formation of several tritium labelled LacCer-protein complexes, including the LacCer-Lyn complex, into plasma membrane lipid rafts. Administration of C18-[3H]LacCer-(N3) to cells, however, did not result in the formation of LacCer-Lyn complex. These results suggest that LacCer derivatives mimic the biological properties of natural LacCer species and can be utilized as tools to study LacCer-protein interactions, and confirm a specific direct interaction between LacCer species containing very long fatty acids, and Lyn protein, associated with the cytoplasmic layer via myristic/palmitic chains.

18 February 2014 in Human Reproduction
Verified
Journal Article
Open access
PDF file
NSNopparat Srakaew
Nopparat Srakaew
CYCharlene D. Young
Charlene D. Young
ASArpornrad Saewu
Arpornrad Saewu
HXHongbin Xu
Hongbin Xu
KQKrista L. Quesnel
Krista L. Quesnel
NTNongnuj Tanphaichitr
Nongnuj Tanphaichitr
Does antimicrobial peptide, LL-37, inhibit sperm fertilizing ability? Our results indicate that LL-37 inhibits mouse and human sperm fertilizing ability. LL-37, a cationic antimicrobial peptide, exerts its microbicidal effects through the disruption of microbial cytoplasmic membranes following its interaction with microbial surface anionic phospholipids. ALL-38 (an LL-37 close analogue: LL-37 + Ala at the N-terminus) is produced in the vagina 2–6 h post-intercourse from its precursor hCAP-18, a seminal plasma component. At this time, motile sperm have already swum into the uterine cavity, thus unexposed to ALL-38. Since sperm contain a substantial amount of acidic sulfogalactosylglycerolipid (SGG) on their surface, treatment of sperm with LL-37 may cause their membrane disruption in an analogous manner to that occurring on microbial membranes. Mouse/human sperm treated (2–30 min) with LL-37 in a physiological concentration range (up to 10.8 µM) were assessed for SGG-dependent LL-37 binding, and parameters relevant to fertilizing ability, namely motility and intactness of the sperm acrosome and plasma membrane. Ability of mouse sperm to fertilize eggs in vitro was also evaluated. Each study was performed with greater than or equal to three different sperm samples. The efficacy of LL-37 to inhibit sperm fertilizing ability in vivo was determined in female mice (n = 26 each for LL-37 treatment and no treatment), using sperm retrieved from 26 males. Human sperm samples were donated by fertile men. LL-37 was chemically synthesized and was biotinylated for sperm binding studies. Sperm motility was assessed by videomicroscopy and the acrosomal status by Coomassie blue staining of acrosome-intact mouse sperm or the exposure of CD46, an inner acrosomal membrane protein, of acrosome reacted human sperm. Sperm membrane permeabilization/disruption was assessed by the loss of hypo-osmotic swelling response, an incorporation of Sytox Green (a membrane impermeable fluorescent DNA dye), and electron microscopy. Mouse IVF was scored by the presence of two pronuclei in eggs 6 h post-insemination. Ability of mouse sperm to fertilize eggs in vivo was determined by the pregnancy outcome of female mice injected transcervically with sperm with or without LL-37. Biotinylated LL-37 bound to both mouse and human sperm and the binding was partially dependent on sperm surface SGG. Mouse and human sperm became immotile and underwent a premature acrosome reaction upon treatment with LL-37 at 3.6 and 10.8 µM, respectively. The initial action of LL-37 on both mouse and human sperm appeared to be through permeabilization/disruption of sperm surface membranes evidenced by the loss of hypo-osmotic swelling response, Sytox Green staining and electron microscopy revealing ultrastructural damage. Mouse sperm treated with 3.6 µM LL-37 lost the ability to fertilize eggs both in vitro and in vivo. All 26 female mice inseminated with sperm and LL-37 did not become pregnant. No apparent damage to the reproductive tract was observed as revealed by histological characterization in LL-37-inseminated mice and these females resumed fecundity following mating with fertile males. Direct demonstration that LL-37 treated human sperm fail to fertilize eggs was limited by legal restrictions on obtaining human eggs for such use. Our results reveal selective inhibitory effects of LL-37 on sperm fertilizing ability in mice without apparent impairment to the female reproductive tract. LL-37 is therefore a promising candidate to be developed into a vaginal contraceptive with microbicidal activity. This work was supported by Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation (OPP1024509), Canadian Institutes of Health Research (MOP119438 & CCI82413) and International Collaboration and Exchanges NSFC of China (No.30611120525). There are no competing interests to declare.